Arena Pharmaceuticals (FRA:RN3N) 3-Year Book Growth Rate : -3.80% (As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals 3-Year Book Growth Rate?

Arena Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2021 was €9.68.

During the past 12 months, Arena Pharmaceuticals's average Book Value per Share Growth Rate was -40.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -3.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was 48.30% per year. During the past 10 years, the average Book Value per Share Growth Rate was 29.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Arena Pharmaceuticals was 135.30% per year. The lowest was -64.30% per year. And the median was -13.90% per year.

Competitive Comparison of Arena Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Arena Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arena Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's 3-Year Book Growth Rate falls into.

Arena Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Arena Pharmaceuticals (FRA:RN3N) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Arena Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines